LIVN Share Price Performance
US$55.29
3.97 (7.74%)
19.9% undervalued intrinsic discount
US$69.00
Fair Value
Price US$55.29
AnalystConsensusTarget US$69.00
AnalystHighTarget US$79.64
AnalystLowTarget US$54.00
Fair ValueUS$69.00
Share Pricen/a
LivaNova PLC Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
LIVN Community Narratives
AN
Fair Value US$69 19.9% undervalued intrinsic discount
Aging Populations And China Expansion Will Drive Device Adoption
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
Fair Value US$80 30.9% undervalued intrinsic discount
Aging Population And Healthcare Spending Will Drive Neuromodulation Demand
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$56 1.3% undervalued intrinsic discount
Supply Constraints Will Restrain Device Demand But Optimism Emerges
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Aging Populations And China Expansion Will Drive Device Adoption
Key Takeaways Clinical innovation and regulatory momentum are expected to accelerate global adoption of LivaNova's therapies, unlocking new markets and strengthening pricing power and margins. Strategic focus on recurring revenue, service monetization, and operational efficiency should improve earnings quality and support the shift to higher-margin, innovative products.Read more
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
US$69
19.9% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
6.91% p.a.
Profit Margin
10.37%
Future PE
28.41x
Share price in 2028
US$87.44
Aging Population And Healthcare Spending Will Drive Neuromodulation Demand
Key Takeaways Breakthrough p-HGNS and VNS therapies, paired with favorable reimbursement, position LivaNova for sustained growth, recurring revenues, and market outperformance. Strategic global expansion, operational upgrades, and increased procedure volumes provide strong levers for margin improvement and above-average cash flow.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$80
30.9% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
7.46% p.a.
Profit Margin
16.1%
Future PE
21.32x
Share price in 2028
US$100.44
Supply Constraints Will Restrain Device Demand But Optimism Emerges
Key Takeaways Global demographic trends support device demand, but supply chain issues, reimbursement limits, and concentrated product risk restrain growth and threaten sustained market share. Expansion in digital offerings and emerging markets is challenged by geopolitical risks, innovation demands, and dependency on favorable healthcare spending environments.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$56
1.3% undervalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
5.9% p.a.
Profit Margin
12%
Future PE
20.98x
Share price in 2028
US$70.5
Recently Updated Narratives
AN
Aging Populations And China Expansion Will Drive Device Adoption
Fair Value: US$69 19.9% undervalued intrinsic discount
5 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Supply Constraints Will Restrain Device Demand But Optimism Emerges
Fair Value: US$56 1.3% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Population And Healthcare Spending Will Drive Neuromodulation Demand
Fair Value: US$80 30.9% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
LivaNova PLC Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -3.98
- 69.18%
- -16.12%
- 37.5%
About LIVN
- Founded
- 2015
- Employees
- 2900
- CEO
- WebsiteView website
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products and therapies for neurological and cardiac conditions worldwide. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related accessories. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; and devices that deliver neuromodulation therapy for treating difficult-to-treat depression and drug-resistant epilepsy. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
